In 2024, the pulmonary arterial hypertension (PAH) treatment landscape experienced a significant advancement with the approval of a new medication class targeting the activin signalling pathway and the launch of the first single-tablet combination therapy containing both an ERA and PDE-5 inhibitor. These breakthroughs mark a new era of therapeutic possibilities - but they also raise questions about how physician prescribing behaviour may evolve in response.

Using historically tracked real-world data from Ipsos' Pulmonary Hypertension Therapy Monitor between 2020 and 2023, we provide a comprehensive view of treatment patterns in the years leading up to these pivotal changes. Multi-year trends in treatment regimens stratified by patient risk status and functional class highlights actual prescribing habits - a sound basis for any landscaping and predictive activities. These are further enriched by physician-reported drivers of prescription choice, allowing you to understand the motivations and unmet needs of your customer base.

Whether you're tracking early adoption of new therapies, planning a launch strategy, or modelling future market scenarios, this data provides the context and continuity needed to make informed decisions in the PAH space.